Adient Reports First Quarter 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13h ago
0mins
Should l Buy ADNT?
Source: PRnewswire
- Financial Results Announcement: Adient announced its first quarter 2026 financial results, although specific figures were not disclosed, the company emphasized its leadership in the automotive seating sector, which is expected to positively impact future performance.
- Investor Conference Call: CEO Jerome Dorlack and CFO Mark Oswald will host a conference call at 8:30 AM Eastern to discuss the financial results, which is anticipated to attract investor interest and boost market confidence.
- Global Operational Scale: With over 65,000 employees across 29 countries and approximately 200 manufacturing and assembly plants, Adient demonstrates strong global production capacity and market coverage, aiding in meeting the demands of major OEMs.
- Forward-Looking Statement Risks: Adient highlighted several forward-looking statements in its report, emphasizing multiple risks related to the economy, market competition, and supply chains, cautioning investors to carefully assess the uncertainties surrounding future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADNT
Wall Street analysts forecast ADNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADNT is 23.06 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 21.060
Low
20.00
Averages
23.06
High
28.00
Current: 21.060
Low
20.00
Averages
23.06
High
28.00
About ADNT
Adient PLC is an automotive seating supplier company. The Company’s automotive seating solutions include complete seating systems, frames, mechanisms, foam, head restraints, armrests and trim covers. The Company designs, manufactures and markets a full range of seating systems and components for passenger cars, commercial vehicles and light trucks, including vans, pick-up trucks and sport/crossover utility vehicles. The Company manages its business on a geographic basis and operates in three reportable segments: Americas, which is inclusive of North America and South America; Europe, Middle East, and Africa (EMEA), and Asia Pacific/China (Asia). The Company operates approximately 200 wholly- and majority-owned manufacturing or assembly facilities, with operations in approximately 29 countries. The Company provides production and service parts to its customers under multi-year programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adient plc Reports Q1 2026 Earnings with Raised Guidance and Strong Cash Flow
- Revenue Growth: Adient plc reported $3.6 billion in revenue for Q1 2026, marking a 4% year-over-year increase primarily driven by favorable FX impacts from Europe and significant growth in China, effectively offsetting production challenges in North America and demonstrating the company's resilience in global markets.
- Adjusted EBITDA Performance: The adjusted EBITDA for the first quarter stood at $207 million, reflecting a 6% increase compared to the same period last year, with an EBITDA margin of 5.7%, indicating ongoing improvements in cost control and operational efficiency, which bolster confidence in future profitability.
- Shareholder Returns and Liquidity: The company repurchased $25 million in shares during the quarter, ending with a cash balance of $855 million and total liquidity of $1.7 billion, showcasing strong financial health and commitment to shareholders, which is expected to support future investments and growth.
- Outlook Enhancement: Adient raised its full-year 2026 sales guidance to approximately $14.6 billion, with adjusted EBITDA expectations of around $880 million and free cash flow of $125 million, reflecting the company's confidence in future growth, particularly through investments in automation and onshoring opportunities that will drive business performance.
See More
Adient (ADNT) Q1 2026 Earnings Call Transcript
See More
Adient Reports Q1 FY2026 Earnings Beat with Raised Guidance
- Earnings Beat: Adient's Q1 FY2026 non-GAAP EPS of $0.35 exceeded expectations by $0.16, indicating a significant improvement in the company's profitability.
- Revenue Growth: The company reported Q1 revenue of $3.64 billion, a 4.3% year-over-year increase that surpassed market expectations by $160 million, reflecting strong performance amid automotive industry recovery.
- Adjusted EBITDA Improvement: Q1 adjusted EBITDA reached $207 million, an $11 million year-over-year improvement, with adjusted EBITDA margins increasing from 5.6% to 5.7%, showcasing advancements in cost control and operational efficiency.
- Shareholder Returns and Upgraded Outlook: Adient repurchased approximately 1.2 million shares for $25 million in Q1 while raising FY26 revenue and free cash flow guidance to $14.6 billion and $125 million, respectively, reflecting optimism about future business performance.
See More
Adient Reports First Quarter 2026 Financial Results
- Financial Results Announcement: Adient announced its first quarter 2026 financial results, although specific figures were not disclosed, the company emphasized its leadership in the automotive seating sector, which is expected to positively impact future performance.
- Investor Conference Call: CEO Jerome Dorlack and CFO Mark Oswald will host a conference call at 8:30 AM Eastern to discuss the financial results, which is anticipated to attract investor interest and boost market confidence.
- Global Operational Scale: With over 65,000 employees across 29 countries and approximately 200 manufacturing and assembly plants, Adient demonstrates strong global production capacity and market coverage, aiding in meeting the demands of major OEMs.
- Forward-Looking Statement Risks: Adient highlighted several forward-looking statements in its report, emphasizing multiple risks related to the economy, market competition, and supply chains, cautioning investors to carefully assess the uncertainties surrounding future performance.
See More
Adient Set to Announce Q1 Earnings on February 4th
- Earnings Announcement: Adient (ADNT) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimate at $0.19, reflecting a 29.6% year-over-year decline, and revenue estimate at $3.48 billion, down 0.3% year-over-year.
- Performance Expectations: Over the past two years, Adient has met EPS and revenue estimates 50% of the time, indicating a degree of volatility in financial performance that could impact investor confidence moving forward.
- Estimate Revisions: In the last three months, there have been no upward revisions to EPS estimates, with four downward adjustments, while revenue estimates also saw no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
- Competitive Landscape: Despite Adient's joint venture and $1.2 billion wins in China showcasing its restructuring and automation efforts, market analysts suggest that cheaper alternatives may emerge by 2026, posing potential challenges to the company's growth trajectory.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
Adient plc Reports Q1 2026 Earnings with Raised Guidance and Strong Cash Flow
- Revenue Growth: Adient plc reported $3.6 billion in revenue for Q1 2026, marking a 4% year-over-year increase primarily driven by favorable FX impacts from Europe and significant growth in China, effectively offsetting production challenges in North America and demonstrating the company's resilience in global markets.
- Adjusted EBITDA Performance: The adjusted EBITDA for the first quarter stood at $207 million, reflecting a 6% increase compared to the same period last year, with an EBITDA margin of 5.7%, indicating ongoing improvements in cost control and operational efficiency, which bolster confidence in future profitability.
- Shareholder Returns and Liquidity: The company repurchased $25 million in shares during the quarter, ending with a cash balance of $855 million and total liquidity of $1.7 billion, showcasing strong financial health and commitment to shareholders, which is expected to support future investments and growth.
- Outlook Enhancement: Adient raised its full-year 2026 sales guidance to approximately $14.6 billion, with adjusted EBITDA expectations of around $880 million and free cash flow of $125 million, reflecting the company's confidence in future growth, particularly through investments in automation and onshoring opportunities that will drive business performance.
See More
Adient (ADNT) Q1 2026 Earnings Call Transcript
See More
Adient Reports Q1 FY2026 Earnings Beat with Raised Guidance
- Earnings Beat: Adient's Q1 FY2026 non-GAAP EPS of $0.35 exceeded expectations by $0.16, indicating a significant improvement in the company's profitability.
- Revenue Growth: The company reported Q1 revenue of $3.64 billion, a 4.3% year-over-year increase that surpassed market expectations by $160 million, reflecting strong performance amid automotive industry recovery.
- Adjusted EBITDA Improvement: Q1 adjusted EBITDA reached $207 million, an $11 million year-over-year improvement, with adjusted EBITDA margins increasing from 5.6% to 5.7%, showcasing advancements in cost control and operational efficiency.
- Shareholder Returns and Upgraded Outlook: Adient repurchased approximately 1.2 million shares for $25 million in Q1 while raising FY26 revenue and free cash flow guidance to $14.6 billion and $125 million, respectively, reflecting optimism about future business performance.
See More
Adient Reports First Quarter 2026 Financial Results
- Financial Results Announcement: Adient announced its first quarter 2026 financial results, although specific figures were not disclosed, the company emphasized its leadership in the automotive seating sector, which is expected to positively impact future performance.
- Investor Conference Call: CEO Jerome Dorlack and CFO Mark Oswald will host a conference call at 8:30 AM Eastern to discuss the financial results, which is anticipated to attract investor interest and boost market confidence.
- Global Operational Scale: With over 65,000 employees across 29 countries and approximately 200 manufacturing and assembly plants, Adient demonstrates strong global production capacity and market coverage, aiding in meeting the demands of major OEMs.
- Forward-Looking Statement Risks: Adient highlighted several forward-looking statements in its report, emphasizing multiple risks related to the economy, market competition, and supply chains, cautioning investors to carefully assess the uncertainties surrounding future performance.
See More
Adient Set to Announce Q1 Earnings on February 4th
- Earnings Announcement: Adient (ADNT) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimate at $0.19, reflecting a 29.6% year-over-year decline, and revenue estimate at $3.48 billion, down 0.3% year-over-year.
- Performance Expectations: Over the past two years, Adient has met EPS and revenue estimates 50% of the time, indicating a degree of volatility in financial performance that could impact investor confidence moving forward.
- Estimate Revisions: In the last three months, there have been no upward revisions to EPS estimates, with four downward adjustments, while revenue estimates also saw no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
- Competitive Landscape: Despite Adient's joint venture and $1.2 billion wins in China showcasing its restructuring and automation efforts, market analysts suggest that cheaper alternatives may emerge by 2026, posing potential challenges to the company's growth trajectory.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
